Clinical Trials Logo

Locally Recurrent Breast Cancer clinical trials

View clinical trials related to Locally Recurrent Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03786094 Terminated - Clinical trials for Metastatic Breast Cancer

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

FORTRESS
Start date: May 30, 2019
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.

NCT ID: NCT02064829 Completed - Clinical trials for Metastatic Breast Cancer

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

TRIBECA
Start date: March 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

NCT ID: NCT01492101 Completed - Clinical trials for Metastatic Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

BEACON
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.